Special Profile & Four Companies Where Investors are Anticipating Success
June 03 2015 - 7:00AM
InvestorsHub NewsWire
NEW YORK, NY -- June 3, 2015 – About Small Cap Traders and
Four Brief Reports
Small Cap Traders makes the connection between sophisticated
investors and high quality micro and small cap companies that are
currently undervalued. We are an issuer of reports written by
experienced financial analysts and who provide a straight forward
assessment of a profiled company. They include stocks traded in the
NYSE, NASDAQ, and OTCBB exchanges.
*Special Profile* - Two Clinical Stage Products Lead the Way in a
Promising Pipeline and Large
Actinium Pharmaceuticals, Inc. (NYSE-MKT: ATNM), (“the company”) is
a biopharmaceutical company that develops innovative targeted
payload immunotherapeutics for the treatment of advanced cancers.
The company develops cancer drugs, primarily using its Alpha
Particle Immunotherapy Technology (“APIT) platform. This patented
technology combines monoclonal antibodies (mAB) for targeting
specific types of cells with alpha emitting radioisotopes
(actinium-225 and bismuth-213), and specific beta emitting
radiopharmaceuticals, to precisely target and kill cancerous cells.
The Company’s products are based on patented technology
co-developed with Memorial Sloan Kettering Cancer Center
(MSKCC).
Company Highlights
- - Completed secondary offering, resulting in approximately
$18.4 million in proceeds.
- Attained Orphan-Drug Status for Actimab™-A.
- Announced filing for Investigational New Drug meeting with U.S.
FDA to finalize development of Iomab™-B.
- Prepared for Phase 3 Trial of Iomab™-B and Phase 2 Trial of
Actimab™-A by mid-year 2015.
- Merck a leading drug manufacturer holds a large position in
company. (Makin ATNM a Possible Acquisition Target)
For a full analyst report on ATNM that includes a company
overview, market and competition breakdown, recent events, outlook,
valuation, analyst summary and recommendation can be viewed by
using the following link at no cost: http://bit.ly/--ATNM--AnalystReport
Text "SmallCap" to 25827 to receive alerts quicker
4 Brief Reports:
Cellceutix Corp. (OTCBB: CTIX) is a clinical stage
biopharmaceutical company developing innovative therapies with
oncology, dermatology, and antimicrobial applications.
CTIX has updated the progress of two of its leading product
candidates, Kevetrin and Brilacidin-OM. In the report that follows
you can get the details of the progress of these products: http://bit.ly/_CTIX_AnalystBrief
WMIH Corp. (OTCQB: WMIH) operates a single business through their
wholly owned subsidiary, WM Mortgage Reinsurance Company, Inc., a
Hawaii corporation, whose sole activity is the reinsurance of
mortgage insurance policies that is operated in runoff mode.
Investors are anticipating a merger or acquisition for WMIH. Find
out why and get further details in the following report: http://bit.ly/_WMIH_AnalystReport
Sphere 3D Corp. (NASDAQ: ANY) is a virtualization technology
solution provider whose patent pending Glassware 2.0 ultra-thin
client allows fully featured applications to be run on any
cloud-connected device, independent of operating system or
hardware, without sacrificing performance or security.
The company recently announced its new SnapCLOUD platform. Get all
the information when you read the report at the link: http://bit.ly/_ANY_AnalystBrief
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) is a
biopharmaceutical company with a pipeline of novel drug candidates
in clinical trials for the treatment and diagnosis of cancer.
The company presented information about its Phase III bavituximab
agent at a conference. Read about it in the report you will find
here: http://bit.ly/_PPHM_AnalystBrief
Forward-Looking Disclaimer
This report may contain certain forward-looking statements and
information, as defined within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934, and is subject to the Safe Harbor created by those
sections. This material contains statements about expected future
events and/or financial results that are forward-looking in nature
and subject to risks and uncertainties. Such forward- looking
statements by definition involve risks, uncertainties and other
factors, which may cause the actual results, performance or
achievements of mentioned company to be materially different from
the statements made herein.
Compliance Procedure
Content is researched, written and reviewed on a best-effort basis
by a 3rd party research analyst. However, we are only human and may
make mistakes. This report was prepared for informational purposes
only. Affiliated parties involved with producing and issuing
this report have not been compensated in any form by the profiled
company or any related party. A full disclaimer can be found
by viewing the full analyst report. We do not engage in high
frequency trading or hold any positions of profiled company. We
have not been compensated in any form for these reports.
For more information and services provided beyond this release
please use contact information provided below. If you notice any
errors or omissions, please notify us below.
A full disclaimer can be found by viewing the analyst report.
If you wish to have a company covered in more detail by our team,
or wish to learn more about our services, please contact us at
editor@smallcaptraders.com. For any urgent concerns or inquiries
please contact us at editor@smallcaptraders.com.
Source: Small Cap Traders
Contact: editor@smallcaptraders.com
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Sep 2023 to Sep 2024